Press release
Insomnia Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Idorsia Pharmaceutical, Syneos Health, Mochida Pharmaceutical, Merck, Janssen Pharmaceutical, Taisho Pharmaceutical, Takeda
Insomnia Market
Discover which therapies are expected to grab the Insomnia Market Share @ Insomnia Market Outlook- https://www.delveinsight.com/sample-request/insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Insomnia Market Report
• In March 2025, Idorsia Pharmaceuticals Ltd announced a study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder.
• In March 2025, Janssen Research & Development LLC conducted a study is to investigate the effect of JNJ-42847922 (change versus placebo) on sleep efficiency (SE) measured by polysomnography (PSG) after single and multiple dose administration to participants with insomnia disorder without psychiatric comorbidity.
• In March 2025, Taisho Pharmaceuticals organized a phase 2 clinical study of TS-142 in Patients with Insomnia Disorder.
• The total diagnosed prevalent cases of Insomnia in the US comprised approximately 58,617 thousand in 2023 and are projected to increase during the forecast period.
• In 2023, France represented a significant share of diagnosed prevalent cases of insomnia among the EU4 and the UK, accounting for 43% of cases alone, while Spain reported the lowest prevalence at just 11%. This disparity highlights France's predominant role in the regional insomnia landscape compared to Spain's minimal case load.
• DelveInsight's estimates indicate a higher prevalence of insomnia among females compared to males in the US. Specifically, there are approximately 32,685 thousand cases in females versus 25,932 thousand cases in males, reflecting a notable gender disparity in insomnia prevalence.
• The age-specific distribution of diagnosed prevalent cases of insomnia in 2023 showed the highest prevalence among individuals aged 65+ with nearly 2,221 thousand cases and the lowest among those aged 18-24 with approximately 292 thousand cases in Japan.
• EU4 and the UK accounted for around 23,283 thousand diagnosed prevalent cases of Insomnia in 2023. Of these cases, nearly 9,903 thousand and 13,380 thousand cases accounted for acute and chronic insomnia respectively.
• The leading Insomnia Companies such as Idorsia Pharmaceutical, Syneos Health, Mochida Pharmaceutical, Merck, Janssen Pharmaceutical, Taisho Pharmaceutical, Takeda, and others.
• Promising Insomnia Therapies such as QUVIVIQ (daridorexant), BELSOMRA (suvorexant), Seltorexant (JNJ-42847922), TS-142, Ramelteon and zolpidem, and others.
Stay ahead in the Insomnia Therapeutics Market with DelveInsight's Strategic Report @ Insomnia Market Outlook- https://www.delveinsight.com/sample-request/insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Epidemiology Segmentation in the 7MM
• Total Insomnia Diagnosed Prevalent Cases
• Insomnia Type-Specific Cases
• Insomnia Gender-Specific Cases
• Insomnia Age-Specific Cases
Download the report to understand which factors are driving Insomnia Epidemiology trends @ Insomnia Prevalence- https://www.delveinsight.com/sample-request/insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Insomnia Marketed Drugs
• QUVIVIQ (daridorexant): Idorsia Pharmaceutical/ Syneos Health/ Mochida Pharmaceutical
QUVIVIQ (daridorexant), developed by Idorsia Pharmaceuticals, is an orexin receptor antagonist designed to treat insomnia in adults by addressing difficulties with sleep onset and maintenance. By targeting orexin, a neuropeptide that promotes wakefulness, QUVIVIQ reduces nocturnal hyperarousal, enhancing sleep quality without causing next-morning residual effects. Initially developed by Actelion and later acquired by Johnson & Johnson, Idorsia now leads its development. The drug has completed Phase III trials in Japan, with an NDA submitted, as per the company's latest July 2024 corporate presentation. In Japan, Idorsia has a license agreement with Mochida Pharmaceutical for the supply, co-development and comarketing of daridorexant. All potential milestones have been assigned to Nxera. The recommended dose is 25-50 mg taken orally before bed.
• BELSOMRA (suvorexant): Merck
BELSOMRA (suvorexant), developed by Merck, is an orexin receptor antagonist used to treat insomnia by addressing difficulties with sleep onset and maintenance. It works by blocking orexin receptors, which are crucial for promoting wakefulness, thereby reducing wakefulness. BELSOMRA is contraindicated in narcolepsy patients and can impair daytime wakefulness, with CNS depressant effects potentially lasting several days after discontinuation. It is also approved for insomnia in patients with mild-to-moderate Alzheimer's disease. The recommended dose is 10 mg per night, with a maximum of 20 mg if needed and well-tolerated.
Insomnia Emerging Drugs
• Seltorexant (JNJ-42847922): Janssen Pharmaceutical
Seltorexant (JNJ-42847922), developed by Janssen Pharmaceutical, is a selective orexin-2 receptor antagonist for major depressive disorder (MDD) and insomnia. Targeting the orexin system, which regulates arousal and wakefulness, seltorexant aims to address excessive arousal in mood disorders. It is the leading ORX2 antagonist in clinical trials, currently in Phase III for adjunctive MDD treatment with insomnia. Additionally, seltorexant is being explored for Alzheimer's patients exhibiting significant agitation or aggression. Currently as per the company's pipeline the drug is in Phase III for the adjunctive treatment for major depressive disorder with insomnia symptoms (OARS).
TS-142: Taisho Pharmaceutical
TS-142, also known as ORN-0829, is an orexin receptor antagonist developed by Taisho Pharmaceutical for insomnia treatment. It functions as a dual orexin OX1 and OX2 receptor antagonist (DORA) with a short elimination half-life of about 6 hours. Orexins are neuropeptides crucial for regulating wakefulness and the sleep-wake cycle, with OX2 receptors involved in sleep regulation and OX1 receptors supporting REM sleep.
To learn more about Insomnia treatment guidelines, visit @ Insomnia Treatment Market Landscape- https://www.delveinsight.com/sample-request/insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Insomnia Market Outlook
Insomnia, the most prevalent sleep-wake disorder, often remains inadequately treated. It is marked by difficulties with falling or staying asleep, leading to daytime issues such as fatigue, concentration problems, and irritability. The disorder is linked to increased risks of comorbidities, accidents, and workplace impairment. Cognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as a primary treatment by leading sleep organizations but faces challenges like limited access to trained therapists and high costs, leaving pharmacotherapy as a crucial management option.
Insomnia Companies
Idorsia Pharmaceutical, Syneos Health, Mochida Pharmaceutical, Merck, Janssen Pharmaceutical, Taisho Pharmaceutical, Takeda and others.
Insomnia Treatment Market Landscape
The Insomnia treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Insomnia has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.
Learn more about the FDA-approved drugs for Insomnia @ Drugs for Insomnia Treatment- https://www.delveinsight.com/sample-request/insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Insomnia Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Insomnia Companies- Idorsia Pharmaceutical, Syneos Health, Mochida Pharmaceutical, Merck, Janssen Pharmaceutical, Taisho Pharmaceutical, Takeda, and others.
• Insomnia Therapies- QUVIVIQ (daridorexant), BELSOMRA (suvorexant), Seltorexant (JNJ-42847922), TS-142, Ramelteon and zolpidem, and others.
• Insomnia Market Dynamics: Insomnia Market Drivers and Barriers
• Insomnia Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Insomnia Drugs in development @ Insomnia Clinical Trials Assessment- https://www.delveinsight.com/sample-request/insomnia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1 Key Insights
2 Report Introduction
3 Insomnia Market Overview at a Glance
4 Methodology of Insomnia Epidemiology and Market
5 Executive Summary of Insomnia
6 Key Events
7 Disease Background and Overview
8 Insomnia Epidemiology and Patient Population
9 Insomnia Patient Journey
10 Insomnia Marketed Drugs
11 Insomnia Emerging Drugs
12 Insomnia: Market Analysis
13 Key Opinion Leaders' Views
14 SWOT Analysis
15 Insomnia Unmet Need
16 Market Access and Reimbursement
17 Appendix
18 DelveInsight Capabilities
19 Disclaimer
20 About DelveInsight
List of Top Selling Market Research Reports in 2025
Biopsy devices market- https://www.delveinsight.com/report-store/biopsy-devices-market
Diabetic wound market - https://www.delveinsight.com/report-store/diabetic-wounds-market
Joint reconstruction devices market- https://www.delveinsight.com/report-store/joint-reconstruction-devices-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
Spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Cystic fibrosis market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Heart failure market- https://www.delveinsight.com/report-store/congestive-heart-failure-market
NK Cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
Positive airway pressure device market - https://www.delveinsight.com/report-store/positive-airway-pressure-device-market
Stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
Surgical sealant market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Thyroid cancer market- https://www.delveinsight.com/report-store/thyroid-cancer-market
Urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
Intraocular lens market- https://www.delveinsight.com/report-store/intraocular-lens-market
Uterine fibroids market- https://www.delveinsight.com/report-store/uterine-leiomyoma-uterine-fibroids-market
Attention deficit hyperactivity disorder adhd market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
Lymphoedema market- https://www.delveinsight.com/report-store/lymphoedema-market
Dyspepsia market- https://www.delveinsight.com/report-store/functional-dyspepsia-pipeline-insight
Antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-adc-market
Surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
Bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Yash Bhardwaj
info@delveinsight.com
https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Insomnia Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight | Idorsia Pharmaceutical, Syneos Health, Mochida Pharmaceutical, Merck, Janssen Pharmaceutical, Taisho Pharmaceutical, Takeda here
News-ID: 3938246 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Insomnia
Emerging Insomnia Market Trends: Revolutionizing Insomnia Therapeutics With Inno …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Insomnia Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the size of the insomnia market has been on a constant rise. From $5 billion in 2024, the market is projected to expand to $5.24 billion in 2025, marking a compound annual growth rate…
Insomnia Treatment Market: Embrace Restful Nights and Recharge Your Life with Br …
Insomnia, a common sleep disorder, affects millions of people worldwide. The condition not only disrupts the sleep-wake cycle but also affects overall health and quality of life. With the increasing prevalence of insomnia, the demand for effective treatment options has surged, driving the growth of the insomnia treatment market.
Workflows are getting streamlined due to increased connectivity and quicker internet. This is an era of medical IoT, which goes on to…
Insomnia - Drug Pipeline Landscape, 2023
Insomnia is a sleep disorder that is characterized by difficulty falling asleep or staying asleep. Insomnia can be caused by a variety of factors, including stress, anxiety, depression, medications, and medical conditions. Treatment for insomnia typically includes lifestyle changes, such as avoiding caffeine and establishing a regular sleep schedule, as well as cognitive behavioral therapy and, in some cases, medication.
There are two types of insomnia primary and secondary. Primary insomnia…
Insomnia - Drug Pipeline Landscape, 2022
Insomnia is a progressive, degenerative brain disorder that attacks the brain's nerve cells, or neurons, and causes them to waste away. This disease is characterized by a slow, gradual decline in memory, thinking, and reasoning skills. Alzheimer's is the most common form of dementia, accounting for 60 to 80 percent of all cases. Dementia is a general term for a decline in mental ability severe enough to interfere with daily…
Mattress Sydney – Tips For Preventing Insomnia
Having insomnia? Sleeping on a quality mattress Sydney will improve your situation a lot. Insomnia is a condition in which you have a problem to fall asleep or after falling asleep, you have difficulty keeping that condition. However, it is not a disease, but a symptom.
The concept of a good sleep generally differs from person to person. On average, an adult needs 7-8 hours of night sleep for normal functioning…
Insomnia Market Research Report 2026
Global Insomnia Market: Brief Account
The world insomnia market is envisaged to recoup promisingly from its drowsy growth in the past with a number of worthwhile and well-timed opportunities to take advantage of. Insomnia drugs could find an application in the treatment of Parkinson and Alzheimer’s disease as sedatives. The younger population can increase the global demand as intensively as the geriatric group with rising stress levels and persisting diseases…
